GermanyGermany

Cancer immunotherapeutics specialist immatics raises EUR54m

23.09.2010

Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a pivotal Phase III study in advanced renal cell carcinoma (RCC). IMA901 is designed to induce a polyclonal antibody response by 10 different so-called tumour-associated peptides (TUMAPs) that are frequently found to be over-expressed in a large subgroup of patients with renal cell carcinoma. The company said it expects to have first results from the trial (with overall survival as primary endpoint) at the end of 2013. Immatics, which was spun-off from Tuebingen University, also said it will advance its Phase II colorectal cancer vaccine IMA910 and its preclinical project IMA950 in patients with glioblastoma. The financing round was supported by both existing and new investors. Approximately half of the funds came from dievini Hopp Biotech holding, Wellington Partners and other existing shareholders, the other half coming from new investors MIG-advised funds and AT Impf GmbH.

GermanyGermany

11.11.2010

Berlin – Germany has launched a research programme aimed at establishing a bio-based economy by 2030. "Our goal is to support the shift in industrial production from oil-based towards bio-based CO2-neutral, sustainable, and...

GermanyGermany

04.11.2010

Mannheim – German researchers have patented a non-invasive sensor chip that can permanently monitor kidney and liver function. “Our chip can be used for toxicity testing of preclinical drugs in animals. Next year, we are going to...

GermanyGermany

04.11.2010

Planegg-Martinsried – Drug discovery specialist 4SC AG’s oral immunosuppressant Vidofludimus (SC12267, 4SC-101) has provided promisingdata in an exploratory open-label Phase IIa study on 34 patients with inflammatory bowel...

GermanyGermany

04.11.2010

These days, front-page biotech-related headlines are as rare as reports of a sector-driven rally. Supranational threats and crises, on the other hand, are practically everyday events. For instance, it would have been...

GermanyGermany

04.11.2010

Steven M. Zeman, Ph.D., Dr. Franz-Josef Zimmer, European Patent Attorneys at Grünecker Patent- und Rechtsanwälte, Munich

GermanyGermany

03.11.2010

Monheim /West Palm Beach – Bayer CropScience and SentiSearch, Inc. have entered into a two-year research agreement to cooperate in the identification of new molecules targeting odourant receptors in insects. The aim of the...

GermanyGermany

03.11.2010

Dr. Christel Fenge joined Sartorius Stedim Biotech (Göttingen, Aubagne) as VP Marketing for Fermentation Technologies in mid-October. A former General Manager at Recipharm Biologics, Fenge will manage Sartorius’ global business...

GermanyGermany

03.11.2010

A Hanover – Belgian target discovery specialist Galapagos Genomics NV has bagged Europe’s biggest prize for a biotech company. On the evening prior to the opening of the Biotechnica congress-fair in Hanover (October 5th-7th),...

Displaying results 71 to 80 out of 454

< Previous 71-80 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/7/article/cancer-immunotherapeutics-specialist-immatics-raises-eur54-million.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%
  • MORPHOSYS75.99 EUR4.89%

FLOP

  • EPIGENOMICS4.15 EUR-4.38%
  • EVONIK26.20 EUR-2.42%
  • PAION2.80 EUR-2.10%

TOP

  • BIOFRONTERA2.82 EUR28.2%
  • HBM91.50 CHF8.6%
  • EPIGENOMICS4.15 EUR8.4%

FLOP

  • MAGFORCE5.55 EUR-19.6%
  • CO.DON2.65 EUR-15.6%
  • PAION2.80 EUR-13.0%

TOP

  • SANTHERA89.00 CHF2318.5%
  • CO.DON2.65 EUR167.7%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 30.10.2014

Current issue

All issues